No Data
No Data
No Data
No Data
No Data
Estimating The Intrinsic Value Of Pentamaster Corporation Berhad (KLSE:PENTA)
Yahoo FinanceApr 17 19:05 ET
Those Who Invested in Pentamaster Corporation Berhad (KLSE:PENTA) Five Years Ago Are up 164%
Yahoo FinanceMar 31 22:36 ET
Returns On Capital Signal Tricky Times Ahead For Pentamaster Corporation Berhad (KLSE:PENTA)
Yahoo FinanceMar 14 18:14 ET
Pentamaster Well Positioned to Benefit From Growing Medical Devices Industry, Says Mercury Securities
Mercury Securities maintained its "buy" rating for Pentamaster Corp Bhd at RM4.20, with a target price (TP) of RM5.53, based on earnings per share of 16.7 sen forecast for the financial year ending Dec 31, 2024, and a price-earnings ratio of 33 times.
The Edge MarketsMar 6 01:28 ET
Western Bull Securities: Maintaining Benjakoda's (01665) “Buy” Rating and Lowering the Target Price to HK$1.18
Xiniu Securities anticipates that the medical business segment will be the main growth engine for Benjakoda (01665) this year, partially offsetting the impact of the slowing growth of the automotive business segment.
Zhitong FinanceFeb 28 02:19 ET
[Broker Focus] Xiniu Securities slightly lowered the target price of Benjakoda (01665) to HK$1.18 to maintain a “buy” rating
Jinwu Financial News | Xiniu Securities released a research report saying that in fiscal year 2023, Benjakoda (01665) achieved total revenue of about RM690 million (Malaysian currency), an increase of 15.2% over the previous year, and its net profit increased by about 6.7% over the same period last year, which is in line with our expectations. The automotive business segment continued to be the Group's main contributor, accounting for about 47.6% of the Group's total revenue, while the medical business segment increased sharply by 75.2% year-on-year to RM150 million. Thanks to the growth of Factory Automation Solutions (FAS) in the medical business segment, the Group's gross margin increased to 31.9% in the fourth quarter, driven by
金吾財訊Feb 27 03:28 ET
No Data
No Data